PT-141 (Bremelanotide)

The downside is dominated by tolerability and population-specific cardiovascular risk, not by an intrinsic catastrophic signal. The single biggest burden is nausea, common enough to drive nearly one in five users to quit. Blood pressure rises transiently with every dose, which is why cardiovascular disease is an absolute contraindication. Hyperpigmentation and a rare anhedonia signal are the tail risks that keep reversibility from scoring clean. Cost, effort, and opportunity cost are moderate. Dependency is low at on-demand dosing.

Safety Risk (2.8/5.0): Safety is moderate, driven by contraindications and tail risks rather than a fatal signal. In healthy, screened, normotensive people at the label dose, there is no documented life-threatening effect, so the catastrophic floor does not apply. The real concern is cardiovascular: every dose transiently raises blood pressure, and about 1 percent of trial participants recorded readings of 180/110 or higher, per the Vyleesi label, which is why uncontrolled hypertension and known cardiovascular disease are absolute contraindications. A single open-label case of reversible liver enzyme elevation and a mechanistically plausible anhedonia signal round out the watch list, per Pfaus 2022.

Side Effect Profile (3.8/5.0): Side effects are the heaviest practical downside. Nausea affects about 40 percent of users, peaks within an hour or two, and pushes an 18 percent discontinuation rate in the trials, per the Vyleesi label. Flushing hits about 20 percent and headache about 11 percent. The nausea does fade with repeat dosing for most people, dropping sharply by the third dose, but the first encounters can be rough enough that bedtime dosing is the standard workaround.

Financial Cost (3.0/5.0): Cost is moderate and depends heavily on the channel. Branded Vyleesi runs close to 900 dollars for eight doses, while compounded material is roughly 200 to 500 dollars a month and research-grade vials far less. Because use is on-demand and capped at eight doses a month, the per-use cost for an occasional user is manageable rather than punishing.

Time/Effort Burden (3.3/5.0): Effort is real. PT-141 requires a subcutaneous injection, often reconstitution from powder, a 45-minute lead time, and nausea management such as bedtime dosing or a light meal. Tracking the 8-dose monthly cap adds a little overhead. That is more friction than swallowing a pill, though less than a daily-injection peptide.

Opportunity Cost (2.8/5.0): Opportunity cost is moderate. For desire problems, the higher-yield moves are often relationship, stress, sleep, and hormone evaluation, and for men with a blood-flow problem a PDE5 inhibitor is cheaper and oral. PT-141 stacks cleanly with those drugs rather than blocking them, so it does not crowd out alternatives, but spending on it before addressing root causes can.

Dependency/Withdrawal (2.3/5.0): Dependency risk is low at on-demand dosing. PT-141 does not occupy classic reward-reinforcement pathways directly and produces no withdrawal syndrome when used as intended. The one caution comes from continuous, above-label microdosing, where a community experiment reported libido dropping below baseline, a possible downregulation rebound rather than addiction.

Reversibility (2.8/5.0): Reversibility is mostly good with two real exceptions. The drug clears in hours and most effects vanish between doses. But focal hyperpigmentation of the face, gums, or breasts can be slow to fade or permanent in some users, and a documented forum case described persistent, treatment-resistant anhedonia after a single low dose. Those tail risks lift the score above ipamorelin's clean profile.